28 unknown, 13 recruiting, 8 active not recruiting, 8 completed. 63 Phase 3, 19 Phase 2.
Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC | Phase 2 / Phase 3 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 66 | 2026-05-13 | 2026-10-30 |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Zhongshan Hospital | 222 | 2025-12-22 | 2025-12-30 |
| Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib - Hepato Cellular Carcinoma (HCC), Chemotherapy Effect | Phase 3 | Recruiting | Linhui Peng | 326 | 2025-10-31 | 2025-12-16 |
| Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib - Potentially Resectable Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | Shanghai Zhongshan Hospital | 398 | 2025-02-20 | 2026-07-17 |
| Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 37 | 2024-12-01 | 2024-01-03 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma TACE plus camrelizumab and apatinib, Camrelizumab and apatinib - Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization | Phase 3 | Recruiting | Guohui Xu | 101 | 2024-08-10 | 2026-04-14 |
| LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. LM-302, Apatinib, Irinotecan - Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | Active not recruiting | LaNova Medicines Zhejiang Co., Ltd. | 387 | 2024-06-24 | 2026-02-06 |
| Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer Chemotherapy/ADC Regimen, Fluorizoparib, Apatinib - Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer | Phase 3 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2026-01-28 |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2025-08-15 |
| Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant - Advanced Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | Active not recruiting | Fudan University | 184 | 2024-06-11 | 2026-09-25 |
| Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | XIANG YANQUN | 164 | 2024-05-30 | 2024-07-16 |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 AZD0901, Ramucirumab+ paclitaxel, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Active not recruiting | AstraZeneca | 594 | 2024-03-04 | 2026-10-15 |
| Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib - BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 262 | 2023-07-01 | 2025-12-03 |
| A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Standard endocrine therapy plus Apatinib - HR+/HER2-breast Cancer | Phase 3 | Unknown | Fudan University | 916 | 2023-06-01 | 2023-06-05 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Tislelizumab, apatinib, oxaliplatin - Immunotherapy Gastrict Cancer | Phase 2 / Phase 3 | Recruiting | Fujian Cancer Hospital | 130 | 2023-05-10 | 2024-05-01 |
| Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC Camrelizumab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 244 | 2023-05-01 | 2023-05-11 |
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 130 | 2023-01-31 | 2024-12-31 |
Showing 20 of 63. Sign in to see all of them.
Stomach Neoplasms (15) · Carcinoma, Hepatocellular (9) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (3) · Esophageal Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Neoplasms (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Digestive System Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (13) · Sun Yat-sen University (5) · Fudan University (4) · Shanghai Zhongshan Hospital (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Tianjin Medical University Cancer Institute and Hospital (3) · Hebei Medical University (2) · Anhui Provincial Hospital (1) · AstraZeneca (1) · Beijing Chest Hospital (1) · Elevar Therapeutics (1) · Feng Wang (1) · Fujian Cancer Hospital (1) · Fujian Medical University (1) · Fuzhou General Hospital (1)
China (51) · Germany (3) · Italy (3) · Poland (3) · South Korea (3) · Taiwan (3) · United States (3) · France (2) · Hong Kong (2) · Japan (2) · Russia (2) · Spain (2) · Turkey (Türkiye) (2) · Ukraine (2) · United Kingdom (2)
Jin Li, MD, PHD (2) · Shukui Qin, MD (2) · Bang-De Xiang, Ph.D (1) · Chunmei Bai (1) · Feng Wang (1) · Guohui Xu (1) · Han Liang, Master (1) · Hongyun Zhao (1) · Jian Zhou, Doctor (1) · Jianli Zhao (1) · Jianming Xu, Ph.D (1) · Jin Li (1) · Li Zhang, MD (1) · Liang Peng (1) · Liu Tianshu, doctor (1)
PMID 14745444, PMID 20876799, PMID 21443688, PMID 22212563, PMID 23918952, PMID 26020064, PMID 31699150, PMID 32171104, PMID 32508029, PMID 33067126, PMID 33323401, PMID 33490196, PMID 33971141, PMID 34033974, PMID 34913959, PMID 35909569, PMID 37499670, PMID 39232496, PMID 39383487, PMID 39924483, PMID 39961962, PMID 40341124, PMID 41125112, PMID 41308673, PMID 41308676, PMID 41819560
2023 (1)